ASCO21: KEYNOTE-564 demonstrates that Keytruda® extends disease-free survival in clear-cell renal cell carcinoma

Data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (4–8 June 2021) has demonstrated that post-surgery treatment with Keytruda® (pembrolizumab) extends disease-free survival (DFS) for clear cell renal cell carcinoma (RCC) patients.  The findings, from the Phase III KEYNOTE-564 trial, support adjuvant pembrolizumab as a potential new standard of care to reduce disease recurrence in patients with fully resected intermediate to high-risk RCC. “Pembrolizumab may provide a promising treatment for patients for whom there are few therapy options. KEYNOTE-564's DFS supports pembrolizumab as a potential new standard of care in the adjuvant setting to delay disease...